跳至主要内容
临床试验/NCT03548480
NCT03548480已完成不适用

Targeting the Gut Microbiome for Prader-Willi Syndrome Treatment

Fundació Sant Joan de Déu2 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2018年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
39
试验地点
2
主要终点
Change in percent body fat

研究概览

简要总结

The gut microbiome has recently emerged as a major contributor to obesity, systemic inflammation, and metabolic disease. Furthermore, intestinal bacteria are crucial players in the gut-brain axis, regulating a broad range of central nervous system processes, from satiety mechanisms to anxiety and social behavior. Thus, targeting the microbiome is being actively investigated as a therapeutic strategy for a wide array of diseases, including obesity, anxiety, depression, and autism. Among all intestinal bacteria, Bifidobacterium animalis spp. lactis (BAL) has shown promise for obesity treatment in experimental animal models and human subjects, improving body composition and metabolic health, and reducing energy intake. Moreover, tryptophan metabolism, a crucial regulator of satiety mechanisms and anxiety, is a main target of BAL. Given that clinical manifestations of Prader-Willi syndrome (PWS) include hyperphagia, anxiety, altered body composition, and metabolic dysregulation, the aforementioned effects of BAL might prove highly beneficial for children with PWS. Here, the investigators will test this hypothesis by performing a randomized double-blinded placebo-controlled crossover clinical study to assess the effects of BAL supplementation on an array of clinical manifestations of PWS. Children with PWS will undergo a 3-month placebo/probiotic treatment period, a 3-month washout period, followed by a 3-month probiotic/placebo supplementation. Anthropometric, biochemical, and psychological data as well as biological samples will be obtained at the beginning of the study, and after each of the study periods, with a total of four time-points. Specifically, the investigators will determine body composition by DXA analysis; metabolic health by assessing glucose and lipid metabolic parameters as well as circulating hormonal and cytokine levels; thermoregulation by non-invasive thermal imaging; and hyperphagia and emotional and behavioral problems by applying parental-rated validated questionnaires.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
2 Years 至 19 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with Prader-Willi Syndrome with genetic confirmation
  • On a stable diet and medication regimen for at least the last two months before enrollment

排除标准

  • Current enrollment in or discontinuation within the last 30 days from a clinical trial
  • Presence of other medical problems that would preclude study participation
  • Patients with a history of bariatric surgery
  • Unsuitable for inclusion in the study in the opinion of the investigator

结局指标

主要结局

Change in percent body fat

时间窗: 3 months

Measured by DXA scan

次要结局

  • Change in lipid profile (triglyceride, cholesterol)(3 months)
  • Change in glucose metabolic parameters (glucose, insulin, HbA1c)(3 months)
  • Change in thermoregulation(3 months)
  • Change in circulating cytokine levels(3 months)
  • Change in hyperphagia(3 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Targeting the Gut Microbiome for Prader-Willi... | 临床试验